PET and Recovery Following Revascularization (PARR 2)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

430 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-06-30

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rationale: Patients with severe ventricular dysfunction and coronary disease have high morbidity and mortality. They may benefit from revascularization, but have significant peri-operative morbidity and mortality. Positron emission tomography (PET) imaging with F-18-fluorodeoxyglucose (FDG) can detect viable myocardium that may recover from revascularization in such patients. It is unclear whether use of FDG PET in this population is improves outcome or is cost-effective.

Objectives: The principal aim is to determine whether FDG PET-guided therapy is effective versus standard care. Secondary objectives are to determine whether FDG PET-guided therapy improves LV function, quality of life and is good value for money versus standard care.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cardiac FDG PET Viability Registry

NCT00766987

Heart Failure Ischemic Heart Disease Myocardial Dysfunction

COMPLETED

Multi-modality Imaging of Ischemia With 18F-FDG PET and CTA

NCT01520025

Myocardial Ischemia

TERMINATED PHASE4

Early Revascularization in Stable Ischemic Heart Disease Using P.E.T. Imaging

NCT05018247

Ischemic Heart Disease

TERMINATED NA

Improved Prediction of Functional Recovery After Revascularisation Using Combined Assessment of Myocardial Ischaemia and Viability by CMR - Pilot Study

NCT03798652

Cardiovascular Diseases Ischemic Cardiomyopathy Cardiac Ischemia

UNKNOWN

PET-FDG in Myocarditis

NCT03777839

Myocarditis Viral Myocarditis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with severe ventricular dysfunction and coronary artery disease have high morbidity and mortality but may benefit from revascularization. However, there is also significant peri-operative morbidity and mortality among these patients. This accounts for the variable approach to these patients in different cardiac centres. Clearly this patient group has the most to gain when coronary revascularization is beneficial, but also the most to lose when it is not helpful. There is a need for an approach that can better define patients with severe ventricular dysfunction due to ischemia, who will be more likely to benefit from revascularization. Positron emission tomography (PET) imaging with F-18-Fluorodeoxyglucose (FDG) has been used to evaluate patients with ventricular dysfunction, to detect ischemic but viable myocardium more likely to recover from revascularization. Recently retrospective studies have shown that FDG PET can identify patients at high risk for cardiac events if they do not undergo revascularization. However, these studies did not evaluate whether FDG PET actually directed therapy decisions and because of their study design, could not determine whether FDG PET altered patient outcome. Our recent studies have shown that FDG PET can have important impact on therapy decisions and that patients with ischemic but viable myocardium are at increased risk. However it remains unclear whether an approach which utilizes FDG PET to define ischemic but viable myocardium can have a beneficial effect on patient outcome. It is also important to consider the potential clinical impact of FDG PET balanced against its limited availability. In addition, despite the cost of the technology, preliminary data from our group and others suggest a potential cost savings. Accordingly, a prospective randomized study is needed to evaluate whether FDG PET directed therapy has a beneficial effect on patient outcome and is cost-effective.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease Ventricular Dysfunction, Left

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PET guided Therapy

Patients will be randomized to undergo positron emission tomography aspart of their clinical work up

Group Type ACTIVE_COMPARATOR

Positron emission tomography: FDG viability imaging

Intervention Type PROCEDURE

FDG PET viability imaging

PET imaging

Intervention Type OTHER

PET viability imaging

Standard care

Patients will be randomized to standard care will under go other types of imaging or work up for revascularization without PET imaging.

Group Type ACTIVE_COMPARATOR

PET imaging

Intervention Type OTHER

PET viability imaging

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Positron emission tomography: FDG viability imaging

FDG PET viability imaging

Intervention Type PROCEDURE

PET imaging

PET viability imaging

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is \> 18 years of age.
* Documented ejection fraction of \<35% attributable to CAD.
* Documented CAD
* Any patient being considered for revascularization, transplant/heart failure work up or where, in the opinion of the attending physician or surgeon, viability imaging would be considered useful in ongoing clinical management decisions.

Exclusion Criteria

* Other co-morbid conditions making survival unlikely
* \< 6 weeks post myocardial infarction
* CAD unsuitable for revascularization
* emergency revascularization is required.
* severe valvular disease that requires surgery.
* Geographically inaccessible
* Lack of informed consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No